Robust recovery in non-COVID-19 business ensures a beat in Q1
04/05/21 -"Benefiting from strong demand for sample technology solutions and the QuantiFERON-TB test, Qiagen’s non-COVID-19 business was back in the black in Q1 21. Expectedly, COVID-19 products witnessed a ..."
Pages
62
Language
English
Published on
04/05/21
You may also be interested by these reports :
27/10/25
Getinge reported a robust third quarter, with organic sales up 9.5% and adjusted EBITA rising 19%, translating to a 160bps margin expansion to 13.1% ...
27/10/25
Bastide’s FY24/25 underlying results aligned with guidance and our estimates. However, operational improvements were offset by significant ...
23/10/25
Sartorius Stedim Biotech reported an estimate-beating Q3 2025. Revenue was up 12.0%, driven almost entirely by the high-margin consumables business. ...
22/10/25
Sartorius delivered a robust Q3 2025 performance, beating consensus on both revenue and EBITDA, though slightly missing our EBITDA estimate. Revenue ...